Boult Wade Tennant
Bulletins » Use of the EPO’s problem-and-solution approach for assessing inventive step at the UPC

A recent decision (UPC_CFI_501/2023) concerning infringement and validity of European Patent 3,669,828 by the Court of First Instance, Munich Local Division of the Unified Patent Court (UPC) has set out that the problem-and-solution approach developed by the European Patent Office (EPO) should be the primary tool used to assess inventive step in proceedings of the UPC.  The decision stated that this was to ensure legal certainty and to further align the jurisprudence of the UPC with the jurisprudence of the European Patent Office and the EPO’s Boards of Appeal.

The problem-and-solution approach
The EPO’s problem-and-solution approach is a framework for assessing whether an invention shall be considered obvious having regard to the state of the art.  It has been developed by the EPO over a number of years (although its use is not, strictly, a requirement of European practice).  In a simplified form, the problem-and solution approach identifies whether an inventive step is present through the application of the following steps:

  1. Identification of the closest prior art (i.e. the document or other cited prior art that is ‘closest’ to the invention).
  2. Identification of the technical effect conferred by distinguishing feature(s) (or point(s) of novelty) of the claimed invention compared to the closest prior art.
  3. In view of that technical effect, identification of the objective technical problem that is solved by the claimed invention.
  4. Consideration of whether the solution to the technical problem offered by the claimed invention would be obvious to a skilled person starting with knowledge of the closest prior art and in view of, or in combination with, another cited prior art document and/or the skilled person’s common general knowledge.

It is generally accepted that use of the problem-and-solution approach provides an efficient tool for assessment of inventive step by the EPO, providing legal certainty and avoiding ex-post facto conclusions on obviousness of an invention.

Discussion of the problem-and-solution approach within the judgement
The recent decision from the UPC outlines that the problem-and-solution approach should “primarily be applied as a tool to the extent feasible” in order to assess inventive step at the UPC.  The decision states that this would “enhance legal certainty and further align the jurisprudence of the Unified Patent Court with the jurisprudence of the EPO and the Boards of Appeal (BoA)”.

In the discussion of inventive step, the decision noted that in various previous decisions of the UPC the problem-and-solution approach had been applied or referenced, but that in some other cases a different approach had been used – namely the test for inventive step applied by the German Federal Court of Justice.  The present decision remarked that both tests, if correctly applied, should lead to the same results for the majority of cases, and that the use of problem-and-solution is not enshrined in the European Patent Convention.

Nevertheless, the decision notes that, whilst there is a possibility for either test to be used before the UPC, the Division for the present case explicitly chose to apply the problem-and-solution approach.  This is because there is a need for legal certainty for both the users of the system and the various divisions of the Unified Patent Court.  The decision seems to infer that a single approach for assessment of inventive step would be beneficial, and the problem-and-solution approach would be preferred as it offers greater alignment with the jurisprudence of the EPO.

What this means
In general, increased alignment between jurisprudence of the UPC with that of the EPO will be welcomed by most European practitioners.  The problem-and solution approach is a well-established and well-understood tool for any attorney already acting before the EPO.

Having said this, there appeared to be some minor differences in the UPC Division’s consideration of the problem-and-solution approach, not least their use of the description to interpret the meaning and construction of the claims (which, to date, has not been a tactic applied by the EPO in normal circumstances, though the EPO Enlarged Board of Appeal’s recent decision in G1/24 may now align these practices).  Furthermore, the UPC Division also made some mention of whom the appropriate skilled person would be and their incentive or motivation to combine two pieces of prior art.  Typically, this would not be emphasised within the problem-and-solution approach at the EPO, where, in particular, an explicit incentive to combine two prior art documents is not required and an implicit incentive is deemed sufficient.

In view of these slight differences, it is possible that we will see a slightly adapted application of the problem-and-solution approach at the UPC than compared to its application by the EPO.  Time and further case law will make this clear.  It is noted that there are still options to appeal the present decision, and so it remains to be seen if the Court of Appeal for the UPC would apply the same test for inventive step.  Nevertheless, use of the problem-and-solution approach as a foundation for the assessment of inventive step before the UPC provides an element of predictability that will be met with cautious optimism by users of the UPC and their representatives.

For more insights about the Court and the UP system, read the latest from our team here.  You can also register for our UPC newsletter to receive notifications when our insights are published. Contact a member of our UPC Team today.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors